Sorry, you need to enable JavaScript to visit this website.

Colorectal Cancer Screening Guidelines Have Changed—What You Need to Know

We understand. We know it can feel overwhelming to remember when to get screened for which condition. This is especially true for screenings for colorectal cancer, also known as CRC, which were updated just a few years ago. That’s why this March — which is National Colorectal Cancer Awareness Month — we’re sharing some essential details to help you learn when a CRC screening is right for you.

Pfizer Looks Back at 2024 in the Annual Review

Last year, Pfizer celebrated our 175th anniversary. As proud as we are of our nearly two centuries of work, we know that reaching such a milestone is only possible because we don’t take a single year—or single day—for granted. That means both celebrating our accomplishments and relentlessly improving. Today, we’re sharing our Annual Review, which outlines how we did just that in 2024.

Pfizer Announces New Chief Internal Medicine Officer

New York, March 6, 2025 – Pfizer Inc. (NYSE: PFE) today announced that James List, M.D., Ph.D., has joined the company as Chief Internal Medicine Officer. In this role, Dr. List will oversee Pfizer’s Internal Medicine portfolio, from early discovery to late development, inclusive of Medical Affairs and Business Development strategies. He will be responsible for advancing Pfizer’s emerging pipeline of cardiovascular, metabolic, hematologic, and obesity medicines.

Pfizer’s ABRYSVO® Receives Positive CHMP Opinion for Adults Aged 18 to 59

NEW YORK, March 3, 2025 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age.

Pfizer’s Statement on Results of Sixth Annual Pay Equity Study Among Colleagues Worldwide

NEW YORK, N.Y., February 25, 2025 – Pfizer Inc. (NYSE:PFE) announced today that, for the sixth consecutive year, an independent compensation expert confirmed equitable pay practices for employees at Pfizer.

The study assessed pay equity for gender worldwide and for minorities in the United States based on compensation data, including base pay and bonuses. The study measured the difference between similar groups of employees when adjusting for factors such as role, grade, job level, and location.

Subscribe to Updates